Press release
Hyperlipidemia Therapeutics Pipeline - Key Players Analysis Novartis, Eli Lilly and Company, Merck Group
Browse report sample at: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis/report-sample
*Hyperlipidemia Therapeutics Pipeline Involves Drug Candidates with Novel Target
It has been observed that most of the companies are developing drug candidates that involves novel target. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, Inclisiran is under the Phase III stage of development by The Medicines Company for the treatment of hyperlipidemia. The drug candidate is an RNAi that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) protein and RNA interference. It was found that Inclisiran cause sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.
Some of the key players involved in the development of hyperlipidemia therapeutics include Novartis AG, Eli Lilly and Company and Merck & Co. Inc.
Browse report at: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis
*Hyperlipidemia Therapeutics Pipeline is Driven by High Unmet Need
Hyperlipidemia increases cardiovascular risks and lowering elevated Low-Density Lipoprotein-Cholesterol (LDL-C) remains a significant unmet need. Statins are the standard of care available for patients with hypercholesterolemia and are highly effective at lowering LDL-C, with well-documented benefits. However, it is unable to achieve a permanent treatment care for all subset of patients.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hyperlipidemia-therapeutics-pipeline-analysis
A significant subset of patients is unable to tolerate statins due to adverse events, including muscle pain or weakness, increased glucose levels, and in rare and extreme cases, muscle breakdown, kidney failure, and death. Additionally, patients with Heterozygous Familial Hypercholesterolemia (HeFH) or Atherosclerotic Cardiovascular Disease (ASCVD) who require additional LDL-C lowering on top of maximally tolerated statin therapy represent a high-risk patient population with an important unmet medical need.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperlipidemia Therapeutics Pipeline - Key Players Analysis Novartis, Eli Lilly and Company, Merck Group here
News-ID: 1409032 • Views: …
More Releases from P&S Intelligence
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period.
According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven…
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period.
This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.…
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,…
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,…
More Releases for Hyperlipidemia
Top Trends Transforming the Hyperlipidemia Market Landscape in 2025: Revolutiona …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Will the Hyperlipidemia Industry Market Size Be by 2025?
The market size for hyperlipidemia has seen consistent growth over the previous years. Its projected expansion from $20.24 billion in 2024 to $21.03 billion in 2025, represents a compound annual growth rate (CAGR) of 3.9%. Factors contributing to this…
Elevating Demand In The Hyperlipidemia Market Driven By Rising Incidences Of Hea …
The Hyperlipidemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Hyperlipidemia Market?
In the past few years, the hyperlipidemia market has experienced consistent growth. It is projected to increase from $20.24 billion in 2024 to $21.03 billion in 2025,…
Key Trend Reshaping the Hyperlipidemia Market in 2025: Revolutionary Advances in …
What industry-specific factors are fueling the growth of the hyperlipidemia market?
The prevalence of chronic ailments like heart disease is anticipated to drive the advancement of the hyperlipidemia market. Hyperlipidemia treatments are beneficial to individuals with heart conditions, as they lower heart attack risks, help in stroke prevention, enhance endothelial function, and minimize the requirement for invasive procedures. For example, the British Heart Foundation provided data in September 2024 citing that…
Prominent Hyperlipidemia Market Trend for 2025: Revolutionary Advances in Hyperl …
What Are the Projected Growth and Market Size Trends for the Hyperlipidemia Market?
The hyperlipidemia market is expected to grow from $20.24 billion in 2024 to $21.03 billion in 2025, at a CAGR of 3.9%. This growth is attributed to the increasing demand for effective treatments, growing public awareness, geographic expansion, and factors such as tobacco use.
The Hyperlipidemia market will grow to $24.3 billion by 2029 at a CAGR of 3.7%.…
Hyperlipidemia Treatment Market Size 2034
Hyperlipidemia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Hyperlipidemia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Hyperlipidemia Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Hyperlipidemia, historical and forecasted epidemiology as well…
Hyperlipidemia Market Trends 2024-2033: Outlook and Insights
"The Business Research Company recently released a comprehensive report on the Global Vanadium Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, the vanadium market size has grown…
